Enhancing antitumor efficacy
The understanding of the relationship between cancer and the immune system has evolved substantially during recent years. The efficacy of various cancer immunotherapies, such as oncolytic virotherapy, monoclonal antibodies, cytokines, and cell-based therapies, has been demonstrated in clinical studies. However, in some cancers and some patients, the anticipated effect of monotherapy is less pronounced. In order to improve outcomes, a combination of different immunotherapeutic agents with a different mode of action may be synergic to enhance antitumor efficacy.
Benefits of adding oncolytic virotherapy
Recent studies suggest that oncolytic virotherapy may improve the efficacy of checkpoint inhibitor therapy if added to it. This is largely because oncolytic virotherapy by changing the tumor microenvironment induces complementary mechanisms of anti-tumor immune responses. In addition, it doesn’t exacerbate the toxicity of checkpoint inhibitors. Combination of both treatments is without additional safety concerns above those expected for each monotherapy.
A new and promising approach for the treatment of metastatic melanoma
According to literature adding oncolytic virotherapy to checkpoint inhibitor therapy is a potentially new and promising approach for patients with metastatic melanoma and other solid tumors. We have observed the benefits of such a combination in our daily practice, too.
If you are on novel immunotherapies, such as ipilimumab, pembrolizumab, nivolumab or others, we strongly recommend you to consider adding oncolytic virotherapy medication Rigvir, which will likely demonstrate greater efficacy than either therapy alone without an increase in side effect profile.